treatment with decitabine resulted in a similar survival and fewer adverse events compared with ...
Published 2 years ago • 205 plays • Length 5:12Download video MP4
Download video MP3
Similar videos
-
5:24
10-day decitabine vs 3 7 chemotherapy followed by allohsct in older & fit patients with aml
-
3:35
quizartinib advances overall survival in acute myeloid leukaemia patients
-
5:51
ten-day decitabine with venetoclax in acute myeloid leukaemia: updated outcomes across genomic s...
-
7:57
eha22: 10-day decitabine vs. conventional chemotherapy (“3 7”) followed by allografting (hsct) i...
-
5:17
novel therapies for older patients with aml and mds
-
6:17
chemotherapy combination with capecitabine extends survival after pancreatic cancer surgery
-
3:22
james foran: does decitabine maintenance improve survival in older patients with aml?
-
3:50
paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy
-
2:34
decitabine plus venetoclax is comparable to intensive chemotherapy in r/r aml
-
4:36
maintenance decitabine after intensive therapy for aml in older flt3-itd-negative patients
-
9:17
comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in aml based on fitness
-
1:54
risk-adapted therapy: three-day versus five-day oral decitabine in patients with mds
-
5:14
safety and efficacy of combined ruxolitinib and decitabine in patients...
-
1:38
the search for better post-mpn aml treatment: decitabine and ruxolitinib
-
8:55
survival outcomes from the calgb 40603 study in triple-negative breast cancer
-
8:23
gilteritinib improved survival for patients with acute myeloid leukaemia
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
5:48
risk of serious and fatal adverse events with sorafenib use in patients with solid cancers
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc